Search Results 1191-1200 of 17025 for monoclonal antibody

1. Metabolic Biotinylation - Virology, Vector and Vaccine Engineering: Michael A. Barry - Mayo Clinic Research

   Finally, structural compatibility problems are avoided between ligands and vector proteins such that large ligands (for example, antibodies) and nonprotein ...

2. A Study to Evaluate Tazemetostat and Pembrolizumab to Treat Advanced Urothelial Carcinoma - Mayo Clinic

   Patients who have had a prior monoclonal antibody within 4 weeks prior to study day 1 are not eligible. Patients with a known additional malignancy that is ...

3. Safety and Efficacy of B-cell Activating Factor Receptor (BAFFR)-based Chimeric Antigen Receptor T-cells in Subjects with Relapsed or Refractory BAFFR-expressing B-cell Hematologic Malignancies - Mayo Clinic

   For Follicular Lymphoma, patients must have received prior chemoimmunotherapy including an antibody directed against CD20. For Mantle Cell Lymphoma ...

4. A Study of the Safety and Effectiveness of Combined Copaxone and Estriol for Relapsing Remitting Multiple Sclerosis - Mayo Clinic

   Monoclonal antibody; T cell vaccination; Cladribine; Bone marrow transplantation; Azathioprine; Cyclophosphamide; Methotrexate; Mitoxantrone; Cyclosporin ...

5. Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer - Mayo Clinic

   ... monoclonal antibodies, other investigational agent) < 28 days prior to the first dose of study drug. Current or prior use of immunosuppressive medication ...

6. A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1) - Mayo Clinic

   ... antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma. Participation eligibility.

7. A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) - Mayo Clinic

   GSK3511294 (long-acting anti-IL-5) in the past 12 months. 5. Treatment with any of the following monoclonal antibody therapies within 120 days prior to ...

8. Hematology - Clinical trials

   ... antibodies and the factors that may determine disease progression and treatment response. Safety/Efficacy of MEDI-551 in Combination With Immunomodulating ...

9. Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract - Mayo Clinic

   Documented to be RSV-positive as determined by local testing (eg, polymerase chain reaction, direct fluorescence antibody ... monoclonal anti-RSV antibodies ...

10. A Study to Evaluate IMGN632 with Venetoclax and/or Azacitidine to Treat Patients with CD123-Positive Acute Myeloid Leukemia - Mayo Clinic

    Prior known hypersensitivity reactions to monoclonal antibodies (≥ Grade 3). Prior known hypersensitivity reactions to study drugs and/or any of their ...